Bendamustine followed by ofatumumab and ibrutinib in chronic lymphocytic leukemia: primary endpoint analysis of a multicenter, open-label, phase II trial (CLL2-BIO)

The introduction of targeted agents has revolutionized the treatment of chronic lymphocytic leukemia but only few patients achieve a complete remission and minimal residual disease negativity with ibrutinib monotherapy. This multicenter, investigator-initiated, phase II study is evaluating sequentia...

Descripción completa

Detalles Bibliográficos
Autores principales: Cramer, Paula, von Tresckow, Julia, Robrecht, Sandra, Bahlo, Jasmin, Furstenau, Moritz, Langerbeins, Petra, Pflug, Natali, Al-Sawaf, Othman, Heinz, Werner J., Vehling-Kaiser, Ursula, Durig, Jan, Tausch, Eugen, Hensel, Manfred, Sasse, Stephanie, Fink, Anna-Maria, Fischer, Kirsten, Kreuzer, Karl-Anton, Bottcher, Sebastian, Ritgen, Matthias, Kneba, Michael, Wendtner, Clemens-Martin, Stilgenbauer, Stephan, Eichhorst, Barbara, Hallek, Michael
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Fondazione Ferrata Storti 2020
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7849583/
https://www.ncbi.nlm.nih.gov/pubmed/32107341
http://dx.doi.org/10.3324/haematol.2019.223693

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7849583/
https://www.ncbi.nlm.nih.gov/pubmed/32107341
http://dx.doi.org/10.3324/haematol.2019.223693

Ejemplares similares